New approaches for the efficient development of cost-effective manufacturing processes for cell & gene therapies are sorely needed. Long development timelines, large investments and high risks of failure are holding the industry back. To address these acute challenges, Inscripta has developed GenoScaler®, a first of its kind, rapid microbial genome engineering platform.

GenoScaler® is a scalable, low-cost, high-throughput CRISPR-based genome engineering technology stack that can rapidly design, build, and test 10,000+ precision edits across E. coli and S. cerevisiae genomes to efficiently survey and optimize over enzyme, pathway, and genome sequence space, enabling production of myriad products including small molecules, proteins, and plasmid DNA for therapeutics and other synthetic biology applications. Along with integrated, state-of-the-art methods for high-throughput phenotyping, smart automation, scale-up, informatics, and artificial intelligence, the platform is broadly applicable and can accelerate the process of cell & gene therapy manufacturing development by orders of magnitude, resulting in unprecedented gains in speed, efficiency, and performance compared to traditional methods for microbial strain development. The platform is ideally suited to address the urgent need to develop cost-effective manufacturing processes for cell & gene therapies. Please join us to hear more about the platform and how we can leverage it for successful production of your therapeutic products.